FRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today reported its financial results for the three and nine months ended September 30, 2006. For the three months ended September 30, 2006, the Company reported a net loss attributable to common stockholders of $4.2 million, or $(0.27) per share, compared to a net loss attributable to common stockholders of $1.3 million, or $(0.82) per share, for the same period in 2005. The Company ended the third quarter with $53.8 million in cash and cash equivalents.
